Heparin neutralizer. Original demonstration of its clinical utility
DOI:
https://doi.org/10.35954/SM1998.20.1.1Keywords:
Heparin/Captor; Heparin/Neutralizer; Triethylaminoethylcellulose.Abstract
The authors show the clinical utility of triethylaminethylcellulose as uptaking agent or neutraliser of heparin. The mixture of 35 mg of triethylaminethylcellulose with 8 normal heparinized plasmas ‘in vitro’ and 41 heparinized plasmas ‘in vitro’ obtained a reduction in activated partial thromboplastin time (PATT) and in thrombin time (TT) back to its basal values. A similar procedure performed with this neutraliser in 22 plasmas contaminated with heparin, also normalised the results of PATT and TT. In three patients with thromboembolic disease under therapy with heparin, the use of triethylaminoethylcellulose allowed to perform coagulometric techniques for the determination of proteins C and S. The inocuousness of the uptaking agent was demonstrated as PATT values had no modifications in three severe hemophiliacs and ratios were maintained under 2 for the resistance testing to activated protein C in 6 positive plasmas, when triethylaminethylcellulose was used in both situations.
Downloads
Metrics
References
(1) HIRSH J. Heparin. N Engl J Med. 324,22 1565- 1572,1991.
(2) SCHLUETER AJ, PENNEL BJ, OLSON JD. Evaluation of a new protamine titration method to assay heparin in whole blood and plasma. Am J Clin Pathol. 1997;107:511-520.
(3) TRIPLETT DA, HARMS CS, KOEPKE JA. The effect of heparin on the activated partial thromboplastin time. Am J Clin Pathol. 70:556- 559,1978.
(4) HIRSH J, VON AKEN WG, GALLUS AS, DOLLERY CT, CADE JF, YUNGWL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 53:691-695,1976.
(5) EDSON JR, KRIVIT W, WHITE JG. Kaolin partial thromboplastin time: high levels of procoagulants producing shorts clotting times or masking deficiences of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med. 70:463-470, 1967.
(6) BASU D, GALLUS A, HIRSH J, CADE J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 287: 324- 327,1972.
(7) HULL R, RASKOB G, HIRSH J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal vein thrombosis. N Engl J Med. 315:1109- 1114, 1986.
(8) WAKKACHEM: Extracción de heparina plasmática por filtración en columna de ecteola-celulosa. En Manual de Hemostasia y Trombosis.(Grupo CLAHT).8ª ed. 1990,pág.189-190.
(9) HEPARSORB®. Organon Teknika. Catálogo de producto Nº 34175.
(10) DAHLBÄCK B, CARLSSON M, SVENSSON PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl. Acad. Sci.USA 90:1004,1993.
(11) SVENSSON PJ, DAHLBÄCK B. Resistance to activated protein C as a basis for venous thrombosis N Engl J Med. 330:517-22,1994.
(12) DE RONDE H, BERTINA R. Laboratory diagnosis of APC-resistance: A critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 72, 880-886,1994.
(13) WIESINGER K,HOHENWALLNER W. Bestimmung der APC-Resistenz nach enzymatischem Abbau von Heparin durch DadeR Hepzym TM. Berichte der ÖGKC, Jg. 17,135-137,1994.
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
